-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

Benzinga·08/04/2026 12:04:14
Listen to the news
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $301 to $310.